Grade: Pharmaceutical Grade

Factory Location: Xiamen, Fujian

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East

Monthly Production Capacity: 1000kg

Packaging Information: 25kg/drum 1kg/bottle

Delivery Lead Time: 7 days after payment

Sample Provided: yes

Payment Terms: L/L

 

Product Information

 

Product name	Ganciciovir
CAS No.	82410-32-0
Molecular Formula	C9H13N5O4
Molecular Weight	255.231
Quality Standard	99% up, USP
Appearance	White powder

 

COA of Ganciciovir

 

 

Usage

 

Function of Ganciciovir

Ganciclovir (GCV) is suitable for blind cytomegalovirus retinitis caused by severe immune function, AIDS, organ transplantation, malignant tumors, etc., as well as pneumonia, gastroenteritis, liver and central nervous system CMV infections

 

Ganciclovir  is a derivative of acyclovir (ACV). GCV was developed in the United States in 1983, and clinical trials began in 1984. In 1988, the United States, France and the United Kingdom began to sell in 15 countries. Japan implemented clinical trials in 1988, and was manufactured and sold as a rare drug in 1990.